Wednesday, August 26, 2026

Abaxx Exchange June Volume Beat May Across Every Metric as It Fights Viceroy Short Report

Abaxx Technologies is countering a short-and-distort report from Viceroy Research with a multi-front response: hiring Paul Weiss to investigate the claims and contacting regulators MAS and CIRO. The company says Abaxx Exchange's June 2026 trading volume topped May's on every measure.

LM Salvado
LM Salvado

July 9, 2026

Abaxx Exchange June Volume Beat May Across Every Metric as It Fights Viceroy Short Report
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Viceroy Research published a short-and-distort report targeting Abaxx Technologies, and the company answered within days with data, lawyers, and regulators.1 Abaxx Exchange's June 2026 trading volume surpassed May's across every metric, the company said, using the numbers to counter the credibility attack.1

Abaxx retained law firm Paul Weiss to investigate the allegations in the Viceroy report.1 The exchange also proactively contacted two regulators overseeing its operations: Singapore's Monetary Authority of Singapore (MAS) and Canada's CIRO.1 Reaching out to regulators before they inquire is a defensive move meant to signal transparency rather than concealment.

Abaxx issued a public rebuttal to the short-seller report alongside the regulatory outreach.1 Short-and-distort campaigns typically pair negative claims with a short position, betting the stock drops on the news. Exchanges targeted by such reports often face pressure on both their share price and their reputation with counterparties.

The June volume figures are the centerpiece of Abaxx's counter-narrative. By pointing to trading activity that improved month-over-month across every metric tracked, the exchange is arguing its core business kept functioning normally through the attack.1 Strong volume data gives Abaxx a factual reference point that doesn't depend on how the Paul Weiss investigation concludes.

The situation remains active, with sentiment among market watchers described as mixed but improving.1 The multi-front response — legal investigation, regulator contact, public rebuttal, and volume disclosure — reflects a strategy of moving faster than the allegations can spread. Whether MAS or CIRO take further action, and what Paul Weiss's investigation finds, will shape how the episode affects Abaxx's standing with traders and counterparties going forward.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· June 22, 2026
    Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals
  2. [2]Press releaseGlobeNewswire· June 30, 2026
    Raytech Holding Limited Announces Closing of Approximately $6.2 Million Registered Direct Offering of its Ordinary Shares

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com